GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US-China Biomedical Technology Inc (GREY:UCBB) » Definitions » 12-1 Month Momentum %

US-China Biomedical Technology (US-China Biomedical Technology) 12-1 Month Momentum % : N/A% (As of Jun. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is US-China Biomedical Technology 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-22), US-China Biomedical Technology's 12-1 Month Momentum % is N/A%.

The industry rank for US-China Biomedical Technology's 12-1 Month Momentum % or its related term are showing as below:

UCBB's 12-1 Month Momentum % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: -11.63
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of US-China Biomedical Technology's 12-1 Month Momentum %

For the Health Information Services subindustry, US-China Biomedical Technology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US-China Biomedical Technology's 12-1 Month Momentum % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US-China Biomedical Technology's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where US-China Biomedical Technology's 12-1 Month Momentum % falls into.



US-China Biomedical Technology  (GREY:UCBB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US-China Biomedical Technology  (GREY:UCBB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


US-China Biomedical Technology 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of US-China Biomedical Technology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


US-China Biomedical Technology (US-China Biomedical Technology) Business Description

Traded in Other Exchanges
N/A
Address
2 Park Plaza, Suite 400, Irvine, CA, USA, 92614
US-China Biomedical Technology Inc is an early stage biomedical technology and services company. It is engaged in the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with its network of US based doctors and hospitals. It provides services for moving patients from China to the US with an emphasis on the demographics including pre-screening and genetic testing for family members of cancer patients, patients suffering from Diabetes, and general medical services including preventative care and physicals.

US-China Biomedical Technology (US-China Biomedical Technology) Headlines

No Headlines